A multicenter, double-blind, randomized study to evaluate the safety and efficacy of the addition of MK-0431 compared with sulfonylurea therapy in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin monotherapy.

Trial Profile

A multicenter, double-blind, randomized study to evaluate the safety and efficacy of the addition of MK-0431 compared with sulfonylurea therapy in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin monotherapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2016

At a glance

  • Drugs Sitagliptin (Primary) ; Glipizide
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Feb 2014 Results published in the Drugs and Aging.
    • 29 Jun 2010 Positive results from post-hoc analysis on the composite endpopint of lower blood sugar, no hypglycemia and no weight gain presented at the American Diabetes Association 70th Annual Scientific Sessions (ADA 2010).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top